Hormonal
Dual GIP/GLP-1 receptor agonism (tirzepatide) provides superior glycemic control and greater weight loss compared to single GLP-1 receptor agonists (semaglutide) and insulin analogues (degludec, glargine) in patients with Type 2 Diabetes.
For patients with Type 2 Diabetes seeking maximum glucose control and weight loss, dual GIP/GLP-1 agonists like tirzepatide offer superior results compared to standard GLP-1 drugs or insulin. The treatment involves a once-weekly injection with a gradual dose escalation to manage side effects. While gastrointestinal issues like nausea are common, they are generally mild and comparable to other injectable diabetes medications.
Observations from the global registration Phase III trials suggest that tirzepatide (a novel dual GIP/GLP-1 receptor agonist) represent advancement over current GLP-1 analogues, providing enhanced glycaemic and weight benefits with similar gastrointestinal tolerability.
Why this rating
Based on multiple Phase III randomized controlled trials (SURPASS 1-5) with large sample sizes.
Source
Next Step in Incretin-Based Therapy: From Single to Dual Agonism
Subhodip Pramanik et al. · EMJ Diabetes · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →